Sarepta Therapeutics (NASDAQ:SRPT) had its price target upped by stock analysts at JPMorgan Chase & Co. from $75.00 to $95.00 in a research report issued to clients and investors on Wednesday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 15.07% from the company’s current price.
A number of other brokerages also recently issued reports on SRPT. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, December 25th. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 5th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 9th. Barclays reaffirmed a “hold” rating and set a $55.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 23rd. Finally, UBS Group reiterated an “outperform” rating and set a $56.51 target price (down previously from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $73.12.
Sarepta Therapeutics (NASDAQ:SRPT) traded up $1.66 during trading hours on Wednesday, reaching $82.56. The company had a trading volume of 298,789 shares, compared to its average volume of 1,681,275. The stock has a market capitalization of $5,230.00, a price-to-earnings ratio of -103.20 and a beta of 1.51. Sarepta Therapeutics has a 52-week low of $28.14 and a 52-week high of $83.30. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91.
A number of hedge funds have recently modified their holdings of SRPT. J. Goldman & Company acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at about $58,000. Teacher Retirement System of Texas increased its position in Sarepta Therapeutics by 13.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,034 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 724 shares during the period. Prentiss Smith & Co. Inc. increased its position in Sarepta Therapeutics by 772.2% during the 2nd quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the period. Ameritas Investment Partners Inc. acquired a new position in Sarepta Therapeutics during the 1st quarter worth approximately $127,000. Finally, PNC Financial Services Group Inc. increased its position in Sarepta Therapeutics by 150.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the period. Hedge funds and other institutional investors own 85.14% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.